Noxopharm Limited 26 Statement of Changes in Equity Issued capital Reserves Accumulated losses Total equity Consolidated $ $ $ $ Balance at 1 July 2020 41,631,007 2,708,106 (31,466,355) 12,872,758 Loss after income tax expense for the year - - (9,346,749) (9,346,749) Other comprehensive income for the year, net of tax - - - - Total comprehensive income for the year - - (9,346,749) (9,346,749) Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs (note 12) 21,471,650 - - 21,471,650 Issue of options to underwriter (5,111,573) 5,111,573 - - Issue of Director's options - 1,402,345 - 1,402,345 Exercise of options 7,544,451 (594,803) - 6,949,648 Expired options - (479,800) 479,800 - Conversion of collateral shares 267,637 - - 267,637 Vesting of share-based payments (note 26) - 339,698 - 339,698 Conversion of short term loan convertible notes 6,819,388 - - 6,819,388 Balance at 30 June 2021 72,622,560 8,487,119 (40,333,304) 40,776,375 Issued capital Reserves Accumulated losses Total equity Consolidated $ $ $ $ Balance at 1 July 2021 72,622,560 8,487,119 (40,333,304) 40,776,375 Loss after income tax expense for the year - - (18,666,810) (18,666,810) Other comprehensive income for the year, net of tax - - - - Total comprehensive income for the year - - (18,666,810) (18,666,810) Transactions with owners in their capacity as owners: Issue of Director's options - 621,074 - 621,074 Exercise of options 2,013,161 (808,294) - 1,204,867 Expired options - (197,083) 197,083 - Vesting of share-based payments (note 26) - 182,438 - 182,438 Balance at 30 June 2022 74,635,721 8,285,254 (58,803,031) 24,117,944
RkJQdWJsaXNoZXIy MjE2NDg3